BACKGROUND. Epidermal growth factor receptor (EGFR) inhibitors are effective cancer
therapies, but they are reported to cause a rash in> 50% of patients. In the current study, the …

Purpose Previous studies suggest tetracycline and other antibiotics lessen the severity of
epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm …

Abstract Purpose. Rash occurs in> 50% of patients prescribed epidermal growth factor
receptor (EGFR) inhibitors. This study was undertaken to determine whether sunscreen …

Topical and systemic prophylactic measures, which are administered before the
development of epidermal growth factor receptor (EGFR)‐related acneiform rash, are …

Background. Agents targeting the epidermal growth factor receptor (EGFR) are amongst the
most extensively used of the targeted agents in the therapy of some of the most common …

Background Patients treated with epidermal growth factor receptor inhibitors (EGFRIs)
frequently experience dermatologic toxic effects. Whereas the impact of these effects on …

Epidermal growth factor inhibitors (EGFRI), the first targeted cancer therapy, are currently an
essential treatment for many advance‐stage epithelial cancers. These agents have the …

Rash from epidermal growth factor receptor inhibitors is common and negatively impacts the
quality of life of cancer patients. Published guidelines recommend holding cancer therapy if …

The last few years, new therapies targeting the epidermal growth factor receptor (EGFR)
have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies …

Acneiform rash is the most common side effect of epidermal growth factor receptor (EGFR)
inhibitors (EGFRis), and it occurs in 50-100% of patients. This condition can affect the quality …